Related Experiment Videos
Ouabain-like factor
1Second Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan. agoto-tky@umin.u-tokyo.ac.jp
Abstract:
Accumulated evidence has suggested that several sodium pump inhibitors, similar to cardiotonic steroids, are present in the human body. Ouabain-like factor, the most appealing candidate, has been found to be increased with high sodium intake and hypervolaemia, and in essential hypertension, mineralocorticoid hypertension, and pregnancy-induced hypertension. Furthermore, blocking the action of ouabain-like factor with digibind or a novel anti-ouabain agent lowers blood pressure in several models of hypertension. Several important questions remain, however, before it can be concluded that ouabain-like factor is indeed involved in the regulation of sodium homeostasis and blood pressure.
Insights
The human body may produce an endogenous substance called ouabain-like factor, which is linked to high blood pressure. Blocking this factor has lowered blood pressure in hypertension models, suggesting its role in sodium balance.
Area of Science:
- Endocrinology
- Cardiovascular Physiology
- Hypertension Research
Background:
- Evidence suggests endogenous sodium pump inhibitors, akin to cardiotonic steroids, exist in humans.
- Ouabain-like factor (OLF) is a key candidate, elevated in conditions like high sodium intake, hypervolemia, and various hypertension types.
- OLF's involvement in sodium homeostasis and blood pressure regulation is under investigation.
Purpose of the Study:
- To explore the role of endogenous ouabain-like factor in blood pressure regulation.
- To investigate the therapeutic potential of blocking ouabain-like factor in hypertension.
Main Methods:
- Observational studies correlating OLF levels with hypertension and physiological states.
- Experimental studies using digibind or specific anti-ouabain agents to block OLF action.
- Assessment of blood pressure changes in response to OLF blockade in various hypertension models.
Main Results:
- Ouabain-like factor levels are elevated in conditions associated with hypertension, including high sodium intake and hypervolemia.
- Pharmacological blockade of ouabain-like factor with digibind or novel agents demonstrated a reduction in blood pressure.
- These findings were observed across several experimental models of hypertension.
Conclusions:
- Ouabain-like factor is implicated in the pathophysiology of certain hypertensive conditions.
- Blocking the action of ouabain-like factor represents a potential therapeutic strategy for managing hypertension.
- Further research is needed to definitively establish ouabain-like factor's role in sodium homeostasis and blood pressure control.